<DOC>
	<DOCNO>NCT00860262</DOCNO>
	<brief_summary>The primary objective trial demonstrate follow eight week treatment FDC telmisartan 80 mg plus amlodipine 10 mg ( T80/A10 ) superior first line therapy reduce mean seat trough cuff Systolic Blood Pressure [ SBP ] compare monotherapies telmisartan 80 mg ( T80 ) amlodipine 10 mg ( A10 ) patient severe hypertension . A key secondary objective identify duration treatment require demonstrate superiority FDC monotherapies .</brief_summary>
	<brief_title>Telmisartan Amlodipine Fixed Dose Combination FDC Trial Treatment Severe Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Inclusion criterion 1 . Ability provide write informed consent accordance Good Clinical Practice local legislation 2 . Age 18 year old 3 . Patients severe hypertension define SBP great 180 mmHg DBP great 95 mmHg randomisation 4 . Ability stop current antihypertensive therapy without unacceptable risk patient ( Investigators discretion ) Exclusion criterion Mean inclinic seat cuff SBP &gt; /= 200 mmHg and/or Diastolic Blood Pressure [ DBP ] &gt; /= 95 mmHg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>